Table 1.
Demographic and clinical characteristics of overall study cohort, and event and event-free groups.
| Event (N = 905) | Event-free (N = 14,988) | p | |
|---|---|---|---|
| Age, y, mean (SD) | 71.5 (13.0) | 56.5 (17.4) | < 0.01 |
| Male, N (%) | 533 (58.9) | 6625 (44.2) | < 0.01 |
| Follow-up days* | 862.8 (431.6) | 927.8 (442.5) | < 0.01 |
| PAC, mean (SD) | 1356.1 (5137.2) | 522.6 (2824.3) | < 0.01 |
| HTN, N (%) | 609 (67.3) | 6582 (43.9) | < 0.01 |
| DM, N (%) | 361 (39.9) | 2892 (19.3) | < 0.01 |
| Dyslipidemia, N (%) | 426 (47.1) | 6774 (45.2) | 0.27 |
| HF, N (%) | 232 (25.6) | 1140 (7.6) | < 0.01 |
| AMI, N(%) | 65 (7.2) | 456 (3.0) | < 0.01 |
| CAD, N (%) | 187 (20.7) | 1457 (9.7) | < 0.01 |
| PAOD, N (%) | 43 (4.8) | 254 (1.7) | < 0.01 |
| Stroke, N (%) | 141 (15.6) | 1030 (6.9) | < 0.01 |
| CKD, N (%) | 431 (47.6) | 2181 (14.6) | < 0.01 |
| HCM, N (%) | 27 (3.0) | 242 (1.6) | < 0.01 |
| Aspirin, N (%) | 231 (25.5) | 2910 (19.4) | < 0.01 |
| P2Y12 inhibitor, N (%) | 113 (12.5) | 1081 (7.2) | < 0.01 |
| Warfarin, N (%) | 20 (2.2) | 124 (0.8) | < 0.01 |
| NOAC, N( %) | 8 (0.9) | 57 (0.4) | < 0.05 |
| ACEi/ARB, N (%) | 184 (20.3) | 2172 (14.5) | < 0.01 |
| DHP CCB, N (%) | 253 (28.0) | 2369 (15.8) | < 0.01 |
| Diuretics, N (%) | 213 (23.5) | 1058 (7.1) | < 0.01 |
| Class I AAD, N (%) | 5 (0.6) | 103 (0.7) | 0.83 |
| Class III AAD, N (%) | 62 (6.9) | 316 (2.1) | < 0.01 |
| Beta blocker, N (%) | 169 (18.7) | 3039 (20.3) | 0.25 |
| Non-DHP CCB, N (%) | 59 (6.5) | 664 (4.4) | < 0.01 |
Abbreviations: AAD antiarrhythmic drug, ACEi/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, AMI acute myocardial infarction, CAD coronary artery disease, CKD chronic kidney disease, DHP CCB dihydropyridine calcium channel blocker, DM diabetes mellitus, HCM hypertrophic cardiomyopathy, HF heart failure, HTN hypertension, Non-DHP CCB non-dihydropyridine calcium channel blocker, PAOD peripheral arterial occlusive disease, PAC premature atrial complex, PVC premature ventricular complex, NOAC novel oral anticoagulant.
*Represents median follow-up days(SD).